Introduction and Objective: Hybrid closed-loop (HCL) therapy has revolutionized the care for people living with type 1 diabetes (pwT1D). The integration of different technology devices evolves rapidly providing individuals with more options and flexibility. We aimed to assess real-world outcomes of the new HCL system integrating the tubeless Omnipod 5 insulin pump with FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) in pwT1D managed with insulin pump or multiple daily insulin injections (MDI) and CGM in a UK diabetes centre.Methods: Clinical data were collected via a secure online tool. CGM metrics, HbA1c, diabetes distress scale (DDS) score and Gold score (hypoglycemia awareness) changes between baseline and follow-up were assessed. Analysis was performed in SpSS v29.0.Results: In total, 41 individuals [59% female; 83% White; median age 40 years (IQR 29-56) and diabetes duration 19 years (IQR 10-31)] were included. After 8 months (IQR 5-9), time in range (TIR) (70-180 mg/dL) increased by 21.1% (45.1 ± 18.3% at baseline vs 66.2 ± 9.5% at follow-up; P <0.001). Time at 181-250 mg/dL and >250 mg/dL reduced by 5.8% and 16.3%, respectively (P <0.001 for both). Time below range (<69 mg/dL) remained unchanged. Stratified by previous insulin therapy, the increase in TIR was similar between insulin pump (n = 31) and MDI (n = 10) users (19.0 % vs 27.6%, p = 0.1). Baseline HbA1c was 8.1 ± 0.9% (65 ± 10 mmol/mol) and reduced by 0.7% (95% CI -1.0, -0.4; P <0.001) (-7 mmol/mol [95% CI -10, -4]; P <0.001) at follow-up. DDS score decreased by 1.7 (95% CI -2.3, -1.0; P <0.001) and Gold score remained unchanged (2.1 vs 1.7, p = 0.4).Conclusion: The HCL system of Omnipod 5 with FreeStyle Libre 2 Plus CGM is associated with improvements in glycemia and diabetes distress. Insulin pump and MDI users can equally benefit from the system.
A.L. Liarakos: Other Relationship; Dexcom, Inc. K. Su Khin: None. T.S. Crabtree: Other Relationship; Abbott, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation. L. Langeland: None. E. Robinson: None. E.G. Wilmot: Research Support; Abbott. Speaker’s Bureau; Abbott. Advisory Panel; Abbott. Speaker’s Bureau; AstraZeneca. Advisory Panel; Dexcom, Inc. Speaker’s Bureau; Dexcom, Inc., Eli Lilly and Company. Advisory Panel; Eli Lilly and Company. Research Support; embecta. Advisory Panel; embecta. Research Support; Insulet Corporation. Speaker’s Bureau; Insulet Corporation. Advisory Panel; Insulet Corporation, Medtronic. Speaker’s Bureau; Novo Nordisk. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Roche Diabetes Care, Sanofi. Speaker’s Bureau; Sanofi. Advisory Panel; Sinocare Inc. Speaker’s Bureau; Ypsomed AG.
Source link
Leave a Reply